Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation

• Published in: PLoS medicine Vol. 16; no. 4; p. e1002794
• Main Authors: Colman, Rebecca E., Mace, Aurélien, Seifert, Marva, Hetzel, Jonathan, Mshaiel, Haifa, Suresh, Anita, Lemmer, Darrin, Engelthaler, David M., Catanzaro, Donald G., Young, Amanda G., Denkinger, Claudia M., Rodwell, Timothy C.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 30.04.2019; Public Library of Science (PLoS)
• Subjects: Antitubercular agents; Bioinformatics; Capital costs; Clinical isolates; Complexity; Computational biology; Consortia; Control; Cost-Benefit Analysis; Deoxyribonucleic acid; Diagnostic reagents; DNA; DNA sequencing; DNA, Bacterial - analysis; Drug resistance; Drug Resistance, Multiple, Bacterial - genetics; Evaluation; Genetic aspects; Genome-wide association studies; Genomes; Genomic libraries; Genomics; Health surveillance; High-Throughput Nucleotide Sequencing - economics; High-Throughput Nucleotide Sequencing - instrumentation; High-Throughput Nucleotide Sequencing - methods; High-throughput screening (Biochemical assaying); Humans; Infectious diseases; Instrumentation; Laboratories; Maintenance costs; Medical research; Medicine; Microbial drug resistance; Mortality; Mutation; Mycobacterium tuberculosis; Mycobacterium tuberculosis - genetics; Next-generation sequencing; Occupational health; Optimization; Patients; Public health; Reproducibility of Results; Risk factors; Sequence Analysis, DNA - economics; Sequence Analysis, DNA - instrumentation; Sequence Analysis, DNA - methods; Single-nucleotide polymorphism; Time Factors; Tuberculosis; Tuberculosis, Multidrug-Resistant - microbiology; Visualization; Whole genome sequencing; Workflow; Workflow software; California; United States > US; Switzerland; Arizona
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1002794

Accurate, comprehensive, and timely detection of drug-resistant tuberculosis (TB) is essential to inform patient treatment and enable public health surveillance. This is crucial for effective control of TB globally. Whole-genome sequencing (WGS) and targeted next-generation sequencing (NGS) approaches have potential as rapid in vitro diagnostics (IVDs), but the complexity of workflows, interpretation of results, high costs, and vulnerability of instrumentation have been barriers to broad uptake outside of reference laboratories, especially in low- and middle-income countries. A new, solid-state, tabletop sequencing instrument, Illumina iSeq100, has the potential to decentralize NGS for individual patient care. In this study, we evaluated WGS and targeted NGS for TB on both the new iSeq100 and the widely used MiSeq (both manufactured by Illumina) and compared sequencing performance, costs, and usability. We utilized DNA libraries produced from Mycobacterium tuberculosis clinical isolates for the evaluation. We conducted WGS on three strains and observed equivalent uniform genome coverage with both platforms and found the depth of coverage obtained was consistent with the expected data output. Utilizing the standardized, cloud-based ReSeqTB bioinformatics pipeline for variant analysis, we found the two platforms to have 94.0% (CI 93.1%-94.8%) agreement, in comparison to 97.6% (CI 97%-98.1%) agreement for the same libraries on two MiSeq instruments. For the targeted NGS approach, 46 M. tuberculosis-specific amplicon libraries had 99.6% (CI 98.0%-99.9%) agreement between the iSeq100 and MiSeq data sets in drug resistance-associated SNPs. The upfront capital costs are almost 5-fold lower for the iSeq100 ($19,900 USD) platform in comparison to the MiSeq ($99,000 USD); however, because of difference in the batching capabilities, the price per sample for WGS was higher on the iSeq100. For WGS of M. tuberculosis at the minimum depth of coverage of 30x, the cost per sample on the iSeq100 was $69.44 USD versus $28.21 USD on the MiSeq, assuming a 2 × 150 bp run on a v3 kit. In terms of ease of use, the sequencing workflow of iSeq100 has been optimized to only require 27 minutes total of hands-on time pre- and post-run, and the maintenance is simplified by a single-use cartridge-based fluidic system. As these are the first sequencing attempts on the iSeq100 for M. tuberculosis, the sequencing pool loading concentration still needs optimization, which will affect sequencing error and depth of coverage. Additionally, the costs are based on current equipment and reagent costs, which are subject to change. The iSeq100 instrument is capable of running existing TB WGS and targeted NGS library preparations with comparable accuracy to the MiSeq. The iSeq100 has reduced sequencing workflow hands-on time and is able to deliver sequencing results in <24 hours. Reduced capital and maintenance costs and lower-throughput capabilities also give the iSeq100 an advantage over MiSeq in settings of individualized care but not in high-throughput settings such as reference laboratories, where sample batching can be optimized to minimize cost at the expense of workflow complexity and time.